Rosuvastatin- Hanmi Pharmaceuticals

Drug Profile

Rosuvastatin- Hanmi Pharmaceuticals

Alternative Names: HGP 0816

Latest Information Update: 05 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias

Most Recent Events

  • 01 Oct 2016 Hanmi Pharmaceuticals completes phase I trial in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (NCT02941796)
  • 01 Jul 2016 Hanmi Pharmaceuticals initiates phase I trial in Hyperlipidaemia (Combination therapy, In volunteers) in South Korea (NCT02941796)
  • 01 Jun 2016 Hanmi Pharmaceutical completes a phase III trial in Dyslipidaemias (Combination therapy) in South Korea (NCT02899455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top